NaPro Announces Formation of Chemistry Advisory Board
22 April 2004 - 11:30PM
PR Newswire (US)
NaPro Announces Formation of Chemistry Advisory Board BOULDER,
Colo., April 22 /PRNewswire-FirstCall/ -- NaPro BioTherapeutics,
Inc. today announced the formation of a Chemistry Advisory Board
whose charter is to advise on the development of therapeutic agents
for the treatment of cancer. The board includes six research
scientists with backgrounds in pharmacology, chemistry, formulation
science, and drug development. The members are: Valentino Stella,
Ph.D. (Chairman), Mitchell Avery, Ph.D., Leslie Gunatilaka, Ph.D.,
Gunda Georg, Ph.D., Mark Hamann, Ph.D., and Charles Swindell, Ph.D.
Brief backgrounds of the advisory board are given below: Valentino
J. Stella, Ph.D. (Chairman): Dr. Stella currently serves as
Distinguished Professor of Pharmaceutical Chemistry at the
University of Kansas. He is an expert in the area of chemical
kinetics and his research focuses on improving drug delivery
through the use of prodrugs and cyclodextrins. He is the inventor
or co-inventor of Viread(R), Aquavan(R), Fosphenytoin(R), and
Captisol(R). He received his Ph.D. in Analytical Pharmaceutical
Chemistry and Pharmaceutics from the University of Kansas. Mitchell
A. Avery, Ph.D.: Dr. Avery serves as Interim Chair and Professor at
the University of Mississippi's Department of Medicinal Chemistry.
He also holds positions on the Editorial Advisory Board of Current
Medicinal Chemistry and the Brazilian Journal of Pharmaceutical
Sciences. Dr. Avery's research focuses on the discovery and
development of anti-infective agents. He received his Ph.D. in
Organic Chemistry from the University of California at Santa Cruz.
Leslie Gunatilaka, Ph.D.: Dr. Gunatilaka is Director of the
Southwest Center for Natural Products Research and
Commercialization and a Professor in the Office of Arid Land
Studies at the University of Arizona. Dr. Gunatilaka is also a
member of the Arizona Cancer Center, and his research focuses on
identifying anti-cancer agents from plants and microorganisms. Dr.
Gunatilaka received his Ph.D. from the University of London,
England. Gunda I. Georg, Ph.D.: Dr. Georg is University
Distinguished Professor of Medicinal Chemistry at the University of
Kansas. She is also Director of Drug Discovery at the Higuchi
Biosciences Center as well as Director of the Experimental
Therapeutics Program at the Kansas Masonic Cancer Institute. Dr.
Georg is an expert in medicinal chemistry and receives support from
the National Institutes of Health for her research in epothilones
and taxane chemistry. Mark T. Hamann, Ph.D.: Dr. Hamann is
currently an Associate Professor of Pharmacognosy and Associate
Professor of Chemistry and Biochemistry at the University of
Mississippi. Dr. Hamann has done extensive research on the link
between marine natural products and the treatment of disease, and
he is leading a number of investigations studying their potential
as therapeutics for the treatment of cancer. Dr. Hamann received
his Ph.D. from the University of Hawaii. Charles S. Swindell,
Ph.D.: Dr. Swindell is a Managing Director of DSS Partners, LLC and
has extensive experience in the development of oncology drugs. He
is also the inventor of NaPro's semi-synthetic process for
manufacturing paclitaxel. Dr. Swindell was Chairman of the
Department of Chemistry at Bryn Mawr College. Dr. Swindell received
his Ph.D. in organic chemistry from Rice University. About NaPro
BioTherapeutics NaPro BioTherapeutics, Inc. is a pharmaceutical
company focused on the development of therapies for the treatment
of cancer and hereditary disease. For more information about NaPro
and its technologies, visit NaPro's web site at
http://www.naprobio.com/. Forward Looking Statements The statements
in this press release that are not historical facts are
forward-looking statements that represent management's beliefs and
assumptions as of the date of the press release, based on currently
available information. Forward-looking statements can be identified
by the use of words such as "believes," "intends," "estimates,"
"may," "will," "should," "anticipates," "expected" or comparable
terminology or by discussions of strategy, and include statements
regarding the Chemistry Advisory Board providing knowledge in the
area of medicinal chemistry and assisting in the Company's
development of novel treatments for cancer and hereditary disease.
Although the Company believes that the expectations reflected in
such forward-looking statements are reasonable, it cannot assure
that these expectations will prove to be correct. Such statements
involve risks and uncertainties including those factors identified
under the captions "Risk Factors," "Special Note Regarding Forward
Looking Statements" or "Cautionary Note Regarding Forward Looking
Statements" in the Company's documents filed from time to time with
the SEC, including the Company's Annual Report on Form 10-K for the
year ending December 31, 2003 filed with the SEC on March 11, 2004.
Should one or more of these risks materialize (or the consequences
of such a development worsen), or should the underlying assumptions
prove incorrect, actual results could differ materially from those
forecasted or expected. The Company disclaims any intention or
obligation to update publicly or revise such statements whether as
a result of new information, future events or otherwise. For
further information, please contact L. Robert Cohen, Vice
President, Investor Relations of NaPro BioTherapeutics, Inc.,
+1-212-218-8715. DATASOURCE: NaPro BioTherapeutics, Inc. CONTACT:
L. Robert Cohen, Vice President, Investor Relations of NaPro
BioTherapeutics, Inc., +1-212-218-8715; or media, Peter Steinerman,
+1-516-374-3031, for NaPro BioTherapeutics, Inc.; or investors,
Lilian Stern of Stern Investor Relations, +1-212-362-1200, for
NaPro BioTherapeutics, Inc. Web site: http://www.naprobio.com/
Copyright
Napro Biotherapeutics (NASDAQ:NPRO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Napro Biotherapeutics (NASDAQ:NPRO)
Historical Stock Chart
From Jul 2023 to Jul 2024